Optomed Q1: Solid results
Research Note
2021-05-06
11:08
Redeye maintains Optomed's valuation at EUR 13 per share after today's solid Q1 report. In the months ahead, we expect accelerated camera and software revenue growth.
GA
Gergana Almquist
Disclosures and disclaimers